Insider Buying: Nephros (NASDAQ:NEPH) Director Buys 5,000 Shares of Company Stock

Nephros Inc. (NASDAQ:NEPH – Get Free Report) Director Arthur Amron acquired 5,000 shares of the company’s stock in a transaction on Monday, November 16th. The stock was purchased at an average cost of $3.00 per share, for a total transaction of $15,000.00. Following the completion of the purchase, the director directly owned 167,137 shares in the company, valued at $501,411. This trade represents a 3.08% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Nephros Stock Performance

Nephros stock traded down $0.01 during trading hours on Wednesday, reaching $2.89. 97,021 shares of the stock were exchanged, compared to its average volume of 36,752. Nephros Inc. has a 52-week low of $2.66 and a 52-week high of $6.42. The stock has a market cap of $31.41 million, a P/E ratio of 16.06 and a beta of 1.76. The firm’s 50 day moving average is $3.63 and its 200 day moving average is $3.60.

Nephros (NASDAQ:NEPH – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The business had revenue of $5.62 million for the quarter, compared to the consensus estimate of $5.49 million. Nephros had a net margin of 8.86% and a return on equity of 11.55%. Equities research analysts expect that Nephros Inc. will post 0.18 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on NEPH. Weiss Ratings reiterated a “hold (c)” rating on shares of Nephros in a research report on Friday, October 30th. Benchmark restated a “speculative buy” rating on shares of Nephros in a research report on Tuesday, August 18th. Finally, Zacks Research raised shares of Nephros from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $4.00.

Read Our Latest Stock Report on Nephros

Institutional Trading of Nephros

A number of institutional investors have recently bought and sold shares of NEPH. De Lisle Partners LLP acquired a new stake in Nephros in the 2nd quarter valued at about $62,000. BlackRock Inc. acquired a new position in Nephros during the second quarter worth about $67,000. Dimensional Fund Advisors LP lifted its holdings in shares of Nephros by 52.5% in the first quarter. Dimensional Fund Advisors LP now owns 20,745 shares of the company’s stock valued at $62,000 after purchasing an additional 7,144 shares in the last quarter. Navellier & Associates Inc. lifted its holdings in shares of Nephros by 179.6% in the second quarter. Navellier & Associates Inc. now owns 53,479 shares of the company’s stock valued at $191,000 after purchasing an additional 34,353 shares in the last quarter. Finally, Bard Associates Inc. purchased a new stake in shares of Nephros in the second quarter valued at about $421,000. 41.10% of the stock is currently owned by hedge funds and other institutional investors.

Nephros Company Profile

(Get Free Report)

Nephros, Inc. develops and markets water filtration products for medical and commercial applications. Its ultrafiltration products are designed to help reduce waterborne bacteria, viruses and endotoxins. In healthcare, Nephros serves settings such as hospitals and dialysis facilities, where water quality is important to patient care and clinical operations. The company also offers filtration solutions for commercial facilities. Nephros is headquartered in South Orange, New Jersey. Its business focuses on water filtration products and related solutions rather than providing healthcare services directly.

Recommended Stories

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.